Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 150
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Rev Mal Respir ; 37(10): 776-782, 2020 Dec.
Article in French | MEDLINE | ID: mdl-33071064

ABSTRACT

The Pneumo-Quest self-questionnaire was developed to standardize the practice of recollection when welcoming a new patient. It consists of 82 main questions and 34 subsidiary questions to be completed at home by the patients before their first visit to a pulmonologist. This evaluation was carried out on the basis of 137 returned questionnaires. The feasibility (main criterion) was good with 93±5% of the questions answered and an average completion time of 15.1±9.8minutes (mean±SD). The reliability of the responses (secondary criterion) was good with the agreement between the patient's response and the doctor's opinion being excellent or good for the majority of medical histories and treatments, as evidenced by the high values of the kappa coefficient (>0.90; <0.90; <0.75). Patient and physician perception of the questionnaire was good with 99% and 90% positive ratings, respectively. The use of the questionnaire was unhelpful in the course of the consultation in only 2% of cases. Doctors found the tool useful for obtaining a comprehensive history in 87% of cases and patients declared that it helped them "forgot nothing" in 93% of the cases. The questionnaire helped the doctor to identify the patient's problems rapidly in 71% of cases and saved time in 64%. These positive results encourage a wide dissemination of the questionnaire (www.pneumo-quest.com).


Subject(s)
Diagnostic Self Evaluation , Medical History Taking/standards , Pulmonary Medicine/standards , Surveys and Questionnaires/standards , Adolescent , Adult , Aged , Aged, 80 and over , Ambulatory Care , Ambulatory Care Facilities , Feasibility Studies , Female , Humans , Interviews as Topic/standards , Male , Medical History Taking/methods , Medical Records/standards , Middle Aged , Physician-Patient Relations , Pulmonary Medicine/methods , Reference Standards , Reproducibility of Results , Time Factors , Young Adult
2.
Rev Mal Respir ; 26(6): 587-605, 2009 Jun.
Article in French | MEDLINE | ID: mdl-19623104

ABSTRACT

Swallowing disorders (or dysphagia) are common in the elderly and their prevalence is often underestimated. They may result in serious complications including dehydration, malnutrition, airway obstruction, aspiration pneumonia (infectious process) or pneumonitis (chemical injury caused by the inhalation of sterile gastric contents). Moreover the repercussions of dysphagia are not only physical but also emotional and social, leading to depression, altered quality of life, and social isolation. While some changes in swallowing may be a natural result of aging, dysphagia in the elderly is mainly due to central nervous system diseases such as stroke, parkinsonism, dementia, medications, local oral and oesophageal factors. To be effective, management requires a multidisciplinary team approach and a careful assessment of the patient's oropharyngeal anatomy and physiology, medical and nutritional status, cognition, language and behaviour. Clinical evaluation can be completed by a videofluoroscopic study which enables observation of bolus movement and movements of the oral cavity, pharynx and larynx throughout the swallow. The treatment depends on the underlying cause, extent of dysphagia and prognosis. Various categories of treatment are available, including compensatory strategies (postural changes and dietary modification), direct or indirect therapy techniques (swallow manoeuvres, medication and surgical procedures).


Subject(s)
Deglutition Disorders/complications , Pneumonia, Aspiration/etiology , Respiratory Tract Infections/prevention & control , Aged , Anti-Bacterial Agents/therapeutic use , Deglutition Disorders/diagnosis , Deglutition Disorders/etiology , Deglutition Disorders/therapy , Fluoroscopy , Humans , Pneumonia, Aspiration/epidemiology , Pneumonia, Aspiration/therapy , Respiratory Tract Infections/etiology
3.
Rev Mal Respir ; 36(8): 955-961, 2019 Oct.
Article in French | MEDLINE | ID: mdl-31522951

ABSTRACT

Vaccines have saved millions of lives and reduced the severity of many infections. A reduction in vaccination coverage is now reflected in the re-emergence of epidemics of mumps, pertussis, measles and chickenpox. Many people do not recognize the effectiveness of vaccination and fear the side effects. The main concern is the safety of vaccines. Lack of information weighs less than lack of trust in health authorities. The greater responsibility of the individual and the respect for his free will, may lead the authorities to a less vigourous promotion of the "vaccination duty" which is also a social duty. The attitude of individuals is guided by their health beliefs which are often supported by an erroneous perception of risk. In addition, insidious anti-vaccine lobbying plays on fears and uses biased reasoning that the media help to amplify. Thus the analysis of the brakes to vaccination both in the general population and among health professionals, the dismantling of the arguments developed by the anti-vaccine leagues and vigilance with regard to "fake news" should allow a concerted communication, transparent, clear and effective, in order to limit the occurrence of preventable deaths.


Subject(s)
Vaccination Refusal , Health Knowledge, Attitudes, Practice , Humans , Safety , Trust
4.
Rev Mal Respir ; 36(3): 307-325, 2019 Mar.
Article in French | MEDLINE | ID: mdl-30902443

ABSTRACT

Compensation for occupational pulmonary diseases requires the establishment of guidelines based on standardized and objective criteria, in order to provide compensation that is as fair as possible to patients who suffer from them. A review of the elements necessary for the examination of an individual file was carried out by a working group. It is accepted that respiratory functional exploration is the key element in assessing the level of permanent disability in all of these conditions, with the exception of thoracic malignancies. Guiding scales have been developed for the respiratory impairment of three types of conditions: occupational asthma, thoracic malignancy, and other respiratory diseases. Additional criteria for increasing the permanent disability level are also proposed in order to take into account professional prejudice, in particular the possibility or not of continuing the occupational activity, in the same job or after changing to another. For certain respiratory diseases, a periodic reassessment of the initially attributed permanent disability level is recommended as well as the initial one at the time of definitive cessation of occupational activity.


Subject(s)
Disability Evaluation , Lung Diseases/diagnosis , Occupational Diseases/diagnosis , Asthma/diagnosis , Asthma/economics , Asthma/epidemiology , Diagnostic Imaging , Disabled Persons , Exercise Test , Humans , Lung Diseases/complications , Lung Diseases/economics , Lung Diseases/epidemiology , Lung Neoplasms/diagnosis , Lung Neoplasms/economics , Lung Neoplasms/epidemiology , Occupational Diseases/epidemiology , Respiratory Function Tests/methods , Surveys and Questionnaires , Work Capacity Evaluation , Workers' Compensation
5.
J Clin Invest ; 93(1): 26-32, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8282796

ABSTRACT

Because high concentrations of IL-8 are found in the sputum of cystic fibrosis patients, we hypothesized that Pseudomonas aeruginosa (PA) induces the production of IL-8 in airway epithelial cells and in monocytes. Therefore, we incubated the supernatant from PA culture with human transformed bronchial epithelial cells (16-HBE) or with monocytes. The culture medium of 16-HBE cells that had been incubated with PA supernatant for 6 h had chemotactic activity that was inhibited by an antibody to human IL-8. The PA supernatant induced IL-8 production by primary bronchial epithelial cells, by 16-HBE cells, and by monocytes. After incubation with PA supernatant, 16-HBE cells showed a marked increase in the levels of IL-8 gene expression. The PA product responsible for IL-8 production resisted freezing, boiling, and proteolysis. This product was not lipid extractable and was present in a 1-kD filtrate. We conclude that a small molecular mass product of PA stimulates IL-8 production by 16-HBE cells and by monocytes, and that the chemotactic activity produced by 16-HBE cells after exposure to PA is due principally to IL-8.


Subject(s)
Bronchi/metabolism , Chemotaxis, Leukocyte , Interleukin-8/biosynthesis , Monocytes/physiology , Neutrophils/physiology , Pseudomonas aeruginosa/physiology , Blotting, Northern , Cell Line , Cell Line, Transformed , Cells, Cultured , Culture Media , Epithelium/metabolism , Humans , Pseudomonas aeruginosa/classification , Pseudomonas aeruginosa/isolation & purification , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Species Specificity
6.
Rev Mal Respir ; 24(6): 703-23, 2007 Jun.
Article in French | MEDLINE | ID: mdl-17632431

ABSTRACT

INTRODUCTION: In France, the average age for the diagnosis of bronchial carcinoma is 64. It is 76 in the population of over 70. In fact, its incidence increases with age linked intrinsic risk of developing a cancer and with general ageing of the population. Diagnosis tools are the same for elderlies than for younger patients, and positive diagnosis mainly depends on fibreoptic bronchoscopy, complications of which being comparable to those observed in younger patients. STATE OF THE ART: The assessment of dissemination has been modified in recent years by the availability of PET scanning which is increasingly becoming the examination of choice for preventing unnecessary surgical intervention, a fortiori in elderly subjects. Cerebral imaging by tomodensitometry and nuclear magnetic resonance should systematically be obtained before proposing chirurgical treatment. An assessment of the general state of health of the elderly subject is an essential step before the therapeutic decision is made. This depends on the concept of geriatric evaluation: Geriatric Multidimensional Assessment, and the Comprehensive Geriatric Assessment which concerns overall competence of the elderly. PERSPECTIVES: This is a global approach that allows precise definition and ranking of the patient's problems and their impact on daily life and social environment. Certain geriatric variables (IADL, BADL, MMSE, IMC etc) may be predictive of survival rates after chemotherapy or the incidence of complications following thoracic surgery. The main therapeutic principles for the management of bronchial carcinoma are applicable to the elderly subject; long term survival without relapse after surgical resection is independent of age. Whether the oncological strategy is curative or palliative, the elderly patient with bronchial carcinoma should receive supportive treatments. They should be integrated into a palliative programme if such is the case. In fact, age alone is not a factor that should detract from optimal oncological management. CONCLUSIONS: The development of an individual management programme for an elderly patient suffering from bronchial carcinoma should be based on the combination of oncological investigation and comprehensive geriatric assessment.


Subject(s)
Lung Neoplasms/physiopathology , Age Factors , Aged , Aged, 80 and over , Diagnostic Imaging , Geriatric Assessment , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Palliative Care , Patient Care Planning
7.
Rev Mal Respir ; 23(6): 619-28, 2006 Dec.
Article in French | MEDLINE | ID: mdl-17202967

ABSTRACT

Aging is associated with a progressive decrease in lung function. As a consequence of aging, individual's reserve is diminished, but this decrease is heterogeneous between individual subjects. Many factors are involved in the overall decline in lung function. The prevalence of asthma in the elderly is estimated between 6 and 10%. Mortality due to COPD is increasing, especially among older subjects. Older subjects are at an increased risk of developing chronic diseases such as Parkinson's disease, which can have consequences for lung function. Under-nutrition is also common in the elderly and can produce sarcopenia and skeletal muscle dysfunction. The presentation of respiratory disorders may differ in the elderly, especially because of a lack of perception of symptoms such as dyspnea. The impact of bronchodilatators or corticosteroids on respiratory function has not been studied in the elderly. Drugs usually used for the treatment of hypertension or arrhythmias, which are often observed with aging, can have pulmonary toxicity. There is no difference between functional evaluation in younger and older subjects but it is more difficult to find predicted values for older patients. Performing pulmonary function tests in older patients is often difficult because of a higher prevalence of cognitive impairment and/or poor coordination. When assessing pulmonary function in the elderly, the choice of tests will be depend on the circumstances, with the use of voluntary manoeuvres dependent on the condition of the patient.


Subject(s)
Aging , Respiratory Function Tests/methods , Respiratory Tract Diseases/diagnosis , Aged , Algorithms , Asthma/diagnosis , Diagnosis, Differential , France/epidemiology , Humans , Predictive Value of Tests , Prevalence , Pulmonary Disease, Chronic Obstructive/diagnosis , Quality of Life , Respiratory Tract Diseases/epidemiology
8.
Med Mal Infect ; 36(11-12): 538-45, 2006.
Article in French | MEDLINE | ID: mdl-16837158

ABSTRACT

Lower respiratory tract infection is easily suggested on clinical signs (cough and sputum) associated with fever. To discriminate between pneumonia and acute bronchitis is crucial because of the mortality associated with pneumonia and of its specific management. Chest X-ray is a key exam for the diagnosis and should be performed on the basis of validated clinical signs that are however of weak diagnostic value. Clinical as well as radiological signs cannot be reliably used to identify the causative germ. Sputum examination, the search for pneumococcal and legionella urinary antigens are of good diagnostic value. An associated COPD may lead to an acute respiratory failure. Acute exacerbation of chronic bronchitis results from various causes but infection is involved in about 50% of the cases, mostly viral and most often due to a rhinovirus. Viral infection can be associated to bacterial infection and the most frequently isolated germs are Streptococcus pneumoniae, Haemophilus influenzae, and B. catarrhalis. Severity assessment relies on the value of basal FEV1 that is often non available. Therefore Afssaps suggests using a dyspnea index to assess exacerbation severity.


Subject(s)
Respiratory Tract Infections/classification , Adult , Fever/etiology , France/epidemiology , Humans , Pneumonia/epidemiology , Pneumonia/mortality , Pneumonia/physiopathology , Pulmonary Disease, Chronic Obstructive/complications , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/physiopathology
9.
Rev Mal Respir ; 33(10): 911-936, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27890625

ABSTRACT

The Société de Pneumologie de Langue Française proposes a decision algorithm on long-term pharmacological COPD treatment. A working group reviewed the literature published between January 2009 and May 2016. This document lays out proposals and not guidelines. It only focuses on pharmacological treatments except vaccinations, smoking cessation treatments and oxygen therapy. Any COPD diagnosis, based on pulmonary function tests, should lead to recommend smoking cessation, vaccinations, physical activity, pulmonary rehabilitation in case of activity limitation, and short-acting bronchodilators. Symptoms like dyspnea and exacerbations determine the therapeutic choices. In case of daily dyspnea and/or exacerbations, a long-acting bronchodilator should be suggested (beta-2 agonist, LABA or anticholinergics, LAMA). A clinical and lung function reevaluation is suggested 1 to 3 months after any treatment modification and every 3-12 months according to the severity of the disease. In case of persisting dyspnea, a fixed dose LABA+LAMA combination improves pulmonary function (FEV1), quality of life, dyspnea and decreases exacerbations without increasing side effects. In case of frequent exacerbations and a FEV1≤70%, a fixed dose long-acting bronchodilator combination or a LABA+ inhaled corticosteroids (ICS) combination can be proposed. A triple combination (LABA+LAMA+ICS) is indicated when exacerbations persist despite one of these combinations. Dyspnea in spite of a bronchodilator combination or exacerbations in spite of a triple combination should lead to consider other pharmacological treatments (theophylline if dyspnea, macrolides if exacerbations, low-dose opioids if refractory dyspnea).


Subject(s)
Bronchodilator Agents/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Adrenal Cortex Hormones/therapeutic use , Calibration , France , Humans , Oxygen Inhalation Therapy , Pulmonary Medicine , Societies, Medical/standards
10.
Rev Mal Respir ; 33(1): 17-24, 2016 Jan.
Article in French | MEDLINE | ID: mdl-26518257

ABSTRACT

BACKGROUND: Early identification of acute exacerbations of COPD facilitates better care. This study was designed to validate a short questionnaire (Exascore) developed to help patients, relatives and carers to diagnose acute exacerbations. METHOD: We first addressed content validity that allowed the elaboration of two questionnaires, one assessing the current status and the other stable status (transition). The second step tested their construction validity, reproducibility and concomitant validity among 126 COPD patients aged 64.4±9.9 years. They included 56 presenting with an exacerbation and 70 in stable state, of whom 57 completed the questionnaire a second time after 7 days. The diagnosis of exacerbation and assessment of severity (gold standard) were established by the treating respiratory physician and confirmed by two independent experts. RESULTS: Factorial analyses established a "current status" questionnaire comprising 8 items and 2 dimensions. Cronbach's alpha coefficients were satisfactory, 0.867 for "respiratory impact", 0.886 for "psychosocial impact" and 0.886 for the total score. Concomitant validity and reproducibility were also adequate. The transition questionnaire did not obtain convincing psychometric results. CONCLUSIONS: The "current status" Exascore questionnaire satisfies psychometric quality criteria while being usable in clinical practice. It helps in diagnosing acute exacerbations and assessing their intensity. Further studies will need to test the adequacy of proposed thresholds, the factorial structure of the score in healthcare professionals and patients' relatives, and its predictive power.


Subject(s)
Disease Progression , Pulmonary Disease, Chronic Obstructive/diagnosis , Surveys and Questionnaires , Acute Disease , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Psychometrics
12.
Biochim Biophys Acta ; 716(3): 283-9, 1982 Jun 16.
Article in English | MEDLINE | ID: mdl-7115752

ABSTRACT

Because hyperoxia induces early injury to lung endothelial cells and since tolerance to hyperoxia is correlated with increased lung antioxidant enzyme activity, we measured superoxide dismutase, catalase and glutathione peroxidase in both fresh isolates and primary cultures of endothelial cells from pig pulmonary artery and aorta. Cultured endothelial cells were studied at confluency and up to 5 days thereafter under control or hyperoxic conditions. In both types of confluent cell, total and cyanide-insensitive superoxide dismutase increased when compared to fresh cells. The most conspicuous postconfluency change in both types of endothelial cell was a marked decrease in glutathione peroxidase, which could be prevented by the addition of selenomethionine to culture media. A 5-day exposure to hyperoxia resulted in a 2-fold increase in cyanide-insensitive superoxide dismutase in both aortic and pulmonary artery endothelial cells. In view of a similar decrease in DNA in both types of cells despite some differences in enzyme levels, oxygen cytotoxicity could not be related to a particular antioxidant enzyme profile.


Subject(s)
Aorta, Thoracic/enzymology , Catalase/metabolism , Glutathione Peroxidase/metabolism , Peroxidases/metabolism , Pulmonary Artery/enzymology , Superoxide Dismutase/metabolism , Aerobiosis , Animals , Cells, Cultured , Endothelium/enzymology , Kinetics , Swine
13.
J Clin Oncol ; 16(8): 2700-7, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9704720

ABSTRACT

PURPOSE: The clinical indications and economic consequences of human granulocyte colony-stimulating factor (G-CSF) prescription during small-cell lung cancer (SCLC) chemotherapy remain controversial. The aim of this study, based on a Markov model, was to assess the impact of routine G-CSF use in the treatment of SCLC on costs and patient comfort. Markov models allow the modeling SCLC chemotherapy, in which the risk of febrile neutropenia (FN) is continuous over time and may occur more than once. PATIENTS AND METHODS: We used a Markov model to compare three strategies: a chemotherapy dose reduction after FN and nonuse of G-CSF ("never" strategy), secondary use of G-CSF ("CSF if FN" strategy) and primary use of G-CSF ("systematic CSF" strategy). Model baseline probabilities were based on a review of medical records for all patients (n = 39) treated for SCLC in our unit during 1993 (when G-CSF was not used) and on published reductions in the incidence of FN obtained by using G-CSF. Two different types of rewards were used: a cost-utility scale that took into account the costs of FN (CFN) episodes and G-CSF (CCSF) courses; and a comfort-utility scale that took into account the discomfort of FN and G-CSF therapy. Costs were analyzed from the health care payer's perspective and utilities were assessed prospectively in standardized interviews with treated SCLC patients. RESULTS: The never strategy was the least costly ($4,875 [United States] versus $5,816 and $7,690 for CSF if FN and systematic CSF) and gave the highest comfort value (378 U v 365 and 327 for CSF if FN and systematic CSF). Sensitivity analyses showed that the never strategy remains the less costly when the probability of a first FN episode was less than 49%, the probability of FN recurrence was less than 60%, or the CFN was less than $6,077, or the CCSF was greater than $863. In terms of patient comfort, the never strategy was the best choice, except for patients who considered that a course of G-CSF caused little or no discomfort, whether or not it prevented FN. CONCLUSION: Routine use of G-CSF during SCLC chemotherapy is not justified by clinical benefits, improved patient comfort, or economic considerations.


Subject(s)
Carcinoma, Small Cell/economics , Granulocyte Colony-Stimulating Factor/therapeutic use , Lung Neoplasms/economics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Small Cell/therapy , Cost-Benefit Analysis , Decision Trees , Granulocyte Colony-Stimulating Factor/adverse effects , Granulocyte Colony-Stimulating Factor/economics , Humans , Lung Neoplasms/therapy , Markov Chains , Neutropenia/etiology
14.
Rev Mal Respir ; 22(2 Pt 1): 247-55, 2005 Apr.
Article in French | MEDLINE | ID: mdl-16092163

ABSTRACT

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a major health problem. Few data about COPD economic burden are available. METHODS: SCOPE was an observational economical retrospective and prospective study conducted in France in 2001, by 114 general practitioners (GPs) and 57 lung specialists. The aim was to describe the burden of COPD patients and to estimate the annual cost according to severity stages. Health resource utilization was collected by questionnaires over a 12-month period for 285 patients. RESULTS: It was a cost-of-illness analysis. COPD patients followed by a lung specialist were more severe than patients followed by a GP and had a higher level of medical resource consumption. The COPD disease and its complications explained 66% of the total cost. The main cost drivers were inpatient care (35%, or 1509,9 euros/year/patient) and prescription medications (31%, or 1340,6 euros/year/patient). The direct total cost varied according to COPD severity on account of inpatient care and respiratory assistance. DISCUSSION: This study confirmed the economic burden of COPD in France. Actions allowed to slow down the disease's evolution and to anticipate the exacerbation could reduce the cost.


Subject(s)
Health Care Costs , Pulmonary Disease, Chronic Obstructive/economics , Aged , Female , France , Humans , Male , Prospective Studies , Retrospective Studies , Severity of Illness Index
15.
Rev Mal Respir ; 32(7): 747-9, 2015 Sep.
Article in French | MEDLINE | ID: mdl-25480387

ABSTRACT

INTRODUCTION: Catheter-related infection by non-tuberculous mycobacteria is rare but difficult to diagnose and the treatment is not standardized. CASE REPORT: A 64-year-old woman treated for lung cancer with intravenous chemotherapy developed an infection of her totally implanted perfusion device with Mycobacterium chelonae. The infection was cured after surgical removal of the device and treatment with oral clarithromycin. CONCLUSION: Mycobacteria may infect vascular access devices. Rapid diagnosis of such infections allows early treatment.


Subject(s)
Catheter-Related Infections/diagnosis , Mycobacterium Infections, Nontuberculous/microbiology , Administration, Oral , Anti-Bacterial Agents/administration & dosage , Antineoplastic Agents/administration & dosage , Catheter-Related Infections/drug therapy , Clarithromycin/administration & dosage , Cross Infection , Female , Humans , Infusions, Intravenous , Middle Aged , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium chelonae/isolation & purification
16.
Eur J Hum Genet ; 5(3): 149-55, 1997.
Article in English | MEDLINE | ID: mdl-9272738

ABSTRACT

The severity and type of clinical manifestations are variable in patients with cystic fibrosis (CF). The respiratory syndromes in these patients consist of lung infections associated with disseminated bronchiectasis (DB), asthma, and chronic obstructive pulmonary disease. To investigate the possible involvement of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in chronic pulmonary disease in adults, we studied 32 DB patients with a clinically isolated respiratory syndrome. Careful analysis of all the CFTR gene exons and their flanking regions revealed a significantly increased frequency of CFTR gene mutations in these patients. Thirteen CFTR gene mutations were identified in sixteen different alleles. Six of these mutations, which have previously been reported as CF defects, were found on nine alleles. A further four, two of which had not previously been described (D192N and 406-2 AdeltaC), are potentially disease-causing mutations. We also identified three rare substitutions (R31C, L997F, T1220I), which could be involved in mild CFTR gene disease. Four patients were compound heterozygotes, one carried two CFTR gene mutations (possibly allelic) and six were heterozygous for a mutation. These results indicate that CFTR gene mutations may play a role in bronchiectatic lung disease, possibly in a multifactorial context. These findings have implications for genetic counselling of DB patients and their families.


Subject(s)
Bronchiectasis/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Mutation , Adult , Aged , Alleles , Bronchiectasis/etiology , Bronchiectasis/metabolism , Cohort Studies , Cystic Fibrosis/complications , Cystic Fibrosis/genetics , Cystic Fibrosis/metabolism , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , DNA Mutational Analysis , Female , Genotype , Humans , Male , Middle Aged , Phenotype , Polymorphism, Genetic , Sweat/chemistry
17.
Chest ; 119(2): 387-93, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11171713

ABSTRACT

STUDY OBJECTIVES: Upper-airway obstruction (UAO) may be present in patients with Parkinson's disease (PD), and its reversibility after levodopa therapy has been suggested. To investigate the effects of oral intake of levodopa on pulmonary function and UAO criteria in patients with PD, we studied 22 patients with PD. DESIGN: Pulmonary function tests were performed after a 12-h withdrawal of levodopa therapy, and 1 h after oral intake of placebo or levodopa, according to a double-blind, placebo-controlled, crossover study. Six UAO criteria were recorded to detect UAO in patients. UAO was found in 5 of 21 patients on baseline conditions (1 patient could not perform all tests). RESULTS: Among the patients with UAO, after levodopa therapy three of five patients did not meet the four of six required criteria for defining UAO. Levodopa produced its effects on UAO criteria by means of a saw-tooth pattern improvement and/or a decrease below the defined thresholds of the peak inspiratory flow and the FEV(1)/peak expiratory flow (PEF) and FEV(1)/forced expiratory flow after 50% of the FVC (FEV(0.5)) ratios. Levodopa PEF increased by 0.85 L/s in patients with UAO and by 0.24 L/s in patients without UAO, while after placebo it increased by 0.03 L/s in patients with UAO and decreased by 0.16 L/s in patients without UAO (p = 0.02). Whereas in patients without UAO an increase of the FEV(1)/PEF and FEV(1)/FEV(0.5) ratios was observed after placebo and levodopa intake, these ratios decreased after levodopa and increased after placebo in patients with UAO. CONCLUSIONS: These results show that levodopa administration in patients with PD induces significant variations in PEF and UAO ratios (FEV(1)/PEF and FEV(1)/FEV(0.5)).


Subject(s)
Antiparkinson Agents/pharmacology , Levodopa/pharmacology , Parkinson Disease/physiopathology , Respiratory Mechanics/drug effects , Aged , Aged, 80 and over , Airway Obstruction/complications , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Middle Aged , Parkinson Disease/complications , Respiratory Function Tests , Spirometry
18.
Chest ; 109(6): 1430-8, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8769489

ABSTRACT

STUDY OBJECTIVE: The development of BAL in children for both research and clinical purposes has been limited so far by the difficulty in establishing reference values. The aim of the study was (1) to define composition of BAL cellular components in control children and to evaluate the ability of these cells to express various cytokines, and (2) to study modifications of differential cytology and BAL cell cytokine responses in children with interstitial lung disorders. POPULATIONS AND METHODS: Two groups were investigated: a control group of 16 children who were concluded to be free of parenchymal lung disease after complete pulmonary investigation, and a group of 11 children with pulmonary sarcoidosis. Differential cytology was evaluated by standard techniques. BAL cell cytokine expression was studied at the level of messenger RNA (mRNA) by reverse transcription-polymerase chain reaction (RT-PCR) methods. RESULTS: In the control group, differential cell counts appeared to be similar to values reported in adult populations with normal distribution of the data and no influence of age. In this group, no transcripts for interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), IL-6, and transforming (correction of tranforming) growth factor-beta (TGF-beta) could be detected. In children with sarcoidosis, different profiles of IL-1beta, TNF-alpha, IL-6, and TGF-beta expression were individualized which seemed to be related to the activity and/or severity of the disease, IL-6 and TGF-beta mRNA being observed only in the more severe forms. CONCLUSION: These data provide information on BAL cell number and function in children. Characterization of BAL cytokine expression patterns during the course of interstitial lung diseases in children may be of great interest for evaluation of disease activity and/or severity and therefore for planning of therapy.


Subject(s)
Bronchoalveolar Lavage Fluid/cytology , Cytokines/metabolism , Sarcoidosis, Pulmonary/metabolism , Sarcoidosis, Pulmonary/pathology , Actins/genetics , Actins/metabolism , Adolescent , Base Sequence , Blotting, Southern , Bronchoalveolar Lavage Fluid/chemistry , Cell Count , Child , Child, Preschool , Female , Humans , Interleukin-1/genetics , Interleukin-1/metabolism , Lung Compliance , Male , Molecular Sequence Data , Polymerase Chain Reaction , Pulmonary Diffusing Capacity , RNA, Messenger/analysis , Sarcoidosis, Pulmonary/physiopathology , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolism , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
19.
Chest ; 103(2): 500-7, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8432144

ABSTRACT

The mechanisms of impaired arterial oxygenation that occur in certain patients with chronic liver cirrhosis are still debated. In the present study, we investigated nine cirrhotic patients with severe respiratory disability (mean PaO2, 64 +/- 5 mm Hg), using the inert gas elimination technique to assess the distribution of ventilation-perfusion (VA/Q) ratios. We also determined shunt fraction during pure oxygen breathing, both in supine and sitting positions. To test the hypothesis that vasodilating prostaglandins could contribute to alter gas exchange in such patients with cirrhosis, we examined the hemodynamic and gasometric responses to indomethacin, 50 mg IV, in six of them. During baseline conditions, patients had high cardiac index (CI, 4.9 +/- 0.2 L/min/m2), and low pulmonary (PVR, 1.78 +/- 0.37 mm Hg/L/min/m2) or systemic (SVR, 17.7 +/- 1.15 mm Hg/L/min/m2) vascular resistances. Large intrapulmonary shunt fraction was documented in each patient with a mean value of 19.6 +/- 2.7 percent. Small perfusion in low VA/Q areas was associated with shunt in only three patients (2.5 to 5.3 percent of blood flow). Arterial PO2 was negatively related to shunt (p < 0.01) and to the dispersion of blood flow distribution (p < 0.02). There was no difference between measured and predicted PaO2. Shunt estimates from the inert gas and the 100 percent O2 breathing techniques were, respectively, 19.6 +/- 2.7 percent and 21.7 +/- 3.0 percent. During 100 percent oxygen breathing, changing from supine to sitting position decreased PaO2 from 401 +/- 50 to 333 +/- 64 mm Hg (p < 0.02), while O2 shunt remained unchanged, arteriovenous difference widened, and mixed venous PO2 decreased, from 61 +/- 3 to 47 +/- 4 mm Hg (p < 0.001). Indomethacin did not improve gas exchange or VA/Q distribution and did not affect systemic or pulmonary hemodynamics. The results show that in cirrhotic patients with severe respiratory disability, intrapulmonary shunting is the main determinant of impaired gas exchange, with no evidence of a defect in oxygen diffusion or an extrapulmonary shunt. Vasodilating prostaglandins do not appear to contribute to these alterations.


Subject(s)
Liver Cirrhosis/complications , Oxygen/blood , Respiratory Insufficiency/blood , Respiratory Insufficiency/complications , Aged , Arteries , Carbon Dioxide/blood , Chronic Disease , Female , Hemodynamics/drug effects , Humans , Indomethacin/pharmacology , Male , Middle Aged , Pulmonary Circulation , Pulmonary Gas Exchange/drug effects , Respiratory Insufficiency/physiopathology , Ventilation-Perfusion Ratio
20.
Am J Clin Pathol ; 104(1): 72-5, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7611187

ABSTRACT

The purpose of this study was to assess the sensitivity and specificity of the polymerase chain reaction (PCR) on induced sputum (IS) for the diagnosis of Pneumocystis carinii pneumonia (PCP) in HIV-infected patients, as well as its diagnostic value and cost as a routine clinical tool. Forty-nine patients with suspected PCP who had IS were studied and if negative, followed by bronchoalveolar lavage (BAL). Pneumocystis carinii was detected in these samples using standard staining techniques. Polymerase chain reaction was used with IS samples in a blinded fashion. The patients with negative BAL samples were closely monitored for 1 month. In the absence of any clinical or radiologic features of PCP during this period, they were considered as being free of PCP. The cost analysis considered only the direct costs of the various tests in three diagnostic strategies: routine BAL (BAL); IS with standard staining, if negative, followed by BAL (IS); and IS with standard staining followed, if negative, by PCR on IS samples (PCR-IS). Using standard staining P carinii was found in 13 cases (6 IS and 7 BAL). None of the 36 patients with negative BAL developed further signs of PCP. Thus, the prevalence of PCP was 26.5% and the sensitivity and specificity of BAL were 100%. Standard staining of IS had a specificity of 100% and a sensitivity of 46.5%. The sensitivity and specificity of PCR-IS were each 100%. The costs of strategies BAL, IS, and PCR-IS were $14,010, $18,300, and $18,040, respectively. The costs of the BAL strategy depended only on the cost of the relevant tests, whereas the costs of strategies IS and PCR-IS depended on the costs of the tests, the sensitivity of IS with standard staining, and the prevalence of PCP in the test population. The routine clinical use of PCR-IS is currently limited by the time required to obtain the results.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , Pneumocystis/isolation & purification , Pneumonia, Pneumocystis/diagnosis , Polymerase Chain Reaction/standards , Sputum/microbiology , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/epidemiology , Adolescent , Adult , Bronchoalveolar Lavage Fluid/microbiology , Cost-Benefit Analysis , DNA, Fungal/analysis , DNA, Fungal/genetics , Female , Humans , Male , Middle Aged , Pneumocystis/genetics , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/epidemiology , Polymerase Chain Reaction/economics , Prevalence , Prospective Studies , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL